"The Report Major
Depressive Disorder - US Drug Forecast and Market Assessment to 2025
provides information on pricing, market analysis, shares, forecast,
and company profiles for key industry participants. -
MarketResearchReports.biz"
Major
depressive disorder (MDD) is one of the most common psychiatric
diseases worldwide. It is characterized by single or recurrent major
depressive episodes (MDEs), where patients can typically experience
periods of depressed mood, loss of energy, abnormal cognition,
anxiety and suicidal ideation. Similar to other neuropsychiatric
disorders, MDD has a multifaceted and varied etiology, and remains
poorly understood. The MDD market is crowded and competitive, with
more than 30 products available for the treatment of patients, the
majority of which are now available as inexpensive generics. The MDD
market is therefore in a dynamic phase where patent expiries for
historically top-selling products such as Eli Lillys Cymbalta and
Otsuka/BMS Abilify have occurred, and recent launches of
Lundbeck/Takedas Trintellix and Otsuka/Lundbecks Rexulti will be a
significant driver of growth in the 7MM. Growth in the MDD market is
also expected to be driven by the potential introduction of six
promising late-stage pipeline products into the market during the
forecast period, all of which are directed towards
treatment-resistant patients, a significant unmet need.
GlobalData
estimates that the MDD market will undergo a period of steady growth
from 2015 to 2025, mainly attributed to the growth in atypical
antipsychotics and the expected launch of five pipeline
products.GlobalData anticipates that five products in the late-stage
pipeline will enter the MDD market in the US during the forecast
period: Alkermes ALKS-5461, Allergan/Gedeon Richter/Mitsubishi
Tanabes Vraylar, Axsome Therapeutics AXS-05, Janssens esketamine, and
Allergans rapastinel.
View Repoert @
http://www.marketresearchreports.biz/analysis/943641
Scope
- Overview of MDD including
epidemiology, etiology, symptoms, diagnosis, pathology and treatment
guidelines as well as an overview on the competitive landscape.
- Detailed information on the
key drugs in the US including product description, safety and
efficacy profiles as well as a SWOT analysis.
- Sales forecast for the top
drugs in the US from 2015-2025.
- Analysis of the impact of key
events as well the drivers and restraints affecting the US MDD
market.
Reasons to buy
- Understand and capitalize by
identifying products that are most likely to ensure a robust return
- Stay ahead of the competition
by understanding the changing competitive landscape for MDD.
- Effectively plan your M&A
and partnership strategies by identifying drugs with the most
promising sales potential
- Make more informed business
decisions from insightful and in-depth analysis of drug performance
- Obtain sales forecast for
drugs from 2015-2025 in the US.
Get Sample Copy Of This
Report @
Table of Contents
1 Table of Contents 2
1.1 List of Tables 6
1.2 List of Figures 10
2 Introduction 11
2.1 Related Reports 11
2.2 Upcoming Related Reports 12
3 Disease Overview 13
3.1 Etiology and
Pathophysiology 13
3.1.1 Etiology 13
3.1.2 Pathophysiology 14
3.2 Classification 17
3.3 Symptoms and Subtypes of
Major Depressive Disorder 19
3.4 Prognosis 20
3.5 Quality of Life 20
4 Disease Management 21
4.1 Diagnosis and Treatment
Overview 21
4.1.1 Diagnosis 21
4.1.2 Treatment Guidelines 22
4.1.3 Clinical Practice 24
4.2 US 28
5 Competitive Assessment 31
5.1 Overview 31
5.2 Selective Serotonin
Reuptake Inhibitors 33
5.2.1 Lexapro (Escitalopram) 33
5.2.2 Viibryd (Vilazodone) 41
5.2.3 Other Selective Serotonin
Reuptake Inhibitors 45
5.3 Serotonin-Norepinephrine
Reuptake Inhibitors 59
5.3.1 Cymbalta (Duloxetine) 59
5.3.2 Effexor (Venlafaxine) 67
5.3.3 Fetzima (Levomilnacipran)
74
5.3.4 Savella (Milnacipran) 80
5.3.5 Pristiq (Desvenlafaxine)
85
5.4 Multimodal Antidepressants
90
5.4.1 Trintellix (Vortioxetine)
90
5.5 Other Antidepressants 99
5.5.1 Bupropion 99
5.5.2 Symbyax
(Olanzapine/Fluoxetine) 105
5.5.3 Mirtazapine 110
5.5.4 Monoamine Oxidase
Inhibitors 115
5.5.5 Tricyclic Antidepressants
119
For More latest Reports
Under Pharmaceutical Category:
About us
MarketResearchReports.biz
is the most comprehensive collection of market research reports.
MarketResearchReports.Biz services are specially designed to save
time and money for our clients. We are a one stop solution for all
your research needs, our main offerings are syndicated research
reports, custom research, subscription access and consulting
services. We serve all sizes and types of companies spanning across
various industries.
Contact
Mr.
Nachiket
State
Tower
90
Sate Street, Suite 700
Albany,
NY 12207
Tel:
+1-518-621-2074
No comments:
Post a Comment